• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $91 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-8 Mln

Equillium Inc. (EQ) Share Price

$2.50

As on 01-Mar-2024 16:00 EST

up-down-arrow $0.010.40%

  • Prev Close info

    $2.49

  • Day's Openinfo

    $2.55

  • Today's Highinfo

    $2.63

  • Today's Lowinfo

    $2.30

  • Today's Volumeinfo

    248,337

  • 52 Week rangeinfo

    $0.45 - 3.25

Please wait...

Equillium Inc. (EQ) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Equillium (EQ)
247.22 212.89 331.03 171.74 -29.22 -20.50 --
S&P BSE Sensex*
2.17 3.02 9.37 24.23 13.97 15.40 13.33
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 01-Mar-2024  |  *As on 02-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
Equillium (EQ)
-32.08 -71.88 -29.53 58.28 -58.58
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Equillium Inc. (EQ) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Equillium Inc. (EQ)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Equillium Inc. (EQ)

        Executive Chairman

        Mr. Daniel Mark Bradbury

        Co-Founder, President, CEO & Director

        Mr. Bruce D. Steel C.F.A.

        Headquarters

        La Jolla, CA

        FAQs for Equillium Inc. (EQ)

        The total asset value of Equillium Inc. (EQ) stood at $ 83 Mln as on 30-Sep-23

        The share price of Equillium Inc. (EQ) is $2.50 (NASDAQ) as of 01-Mar-2024 16:00 EST. Equillium Inc. (EQ) has given a return of -29.22% in the last 3 years.

        Equillium Inc. (EQ) has a market capitalisation of $ 91 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Equillium Inc. (EQ) is 3.79 times as on 29-Feb-2024, a 0.27% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Equillium Inc. (EQ) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Equillium Inc. (EQ) and enter the required number of quantities and click on buy to purchase the shares of Equillium Inc. (EQ).

        Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California. Address: 2223 Avenida De La Playa, La Jolla, CA, United States, 92037

        The CEO & director of Mr. Daniel Mark Bradbury. is Equillium Inc. (EQ), and CFO & Sr. VP is Mr. Bruce D. Steel C.F.A..

        The promoters of Equillium Inc. (EQ) have pledged 0% of the total equity as on Sep-23.

        Equillium Inc. (EQ) Ratios
        Return on equity(%)
        -26.93
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Equillium Inc. (EQ) was $-8 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $91.31 Mln
        • Revenue (TTM)revenue-information $42.63 Mln
        • Earnings (TTM) earning-information $-7.62 Mln
        • Cash date-information $46.31 Mln
        • Total Debt info $0.93 Mln
        • Insider's Holding 36.47%
        • Liquidity liquidity Moderate
        • 52 Week range week-range $0.45 - 3.25
        • Shares outstanding share-outstanding 35,119,200
        • 7 Years Aggregate:

          CFO: $-85.10 Mln

          EBITDA: $-118.51 Mln

          Net Profit: $-225.76 Mln

        About The Company

        • IPO Date 11-Oct-2018
        • Executive Chairman Mr. Daniel Mark Bradbury
        • Co-Founder, President, CEO & Director Mr. Bruce D. Steel C.F.A.
        • Listing key-listing NASDAQ: EQ
        • Country United States
        • Headquarters headquarters La Jolla, CA
        • Website website https://equilliumbio.com
        • Business

          Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a...  clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. Equillium, Inc. was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. The company was incorporated in 2017 and is headquartered in La Jolla, California. Address: 2223 Avenida De La Playa, La Jolla, CA, United States, 92037  Read more

        share-fund-plan-icon